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Among the chemokines discovered to date, nineteen are presently considered to be relevant in heart disease and are involved in
all stages of cardiovascular response to injury. Chemokines are interesting as biomarkers to predict risk of cardiovascular events in
apparently healthy people and as possible therapeutic targets. Moreover, they could have a role as mediators of crosstalk between
immune and cardiovascular system, since they seem to act as a “working-network” in deep linkage with the autonomic nervous
system. In this paper we will describe the single chemokines more involved in heart diseases; then we will present a comprehensive
perspective of them as a complex network connecting the cardiovascular system to both the immune and the autonomic nervous
systems. Finally, some recent evidences indicating chemokines as a possible new tool to predict cardiovascular riskwill be described.
1. Introduction
Chemokines are a subgroup of cytokines with the specific
function of chemoattraction (chemotactic cytokines) and a
molecular weight between 7 and 12 kDa. They are small
molecules of approximately 70 amino acid residues derived
from a single ancestral gene about 650 million years ago
[1]. Chemokines are characterized by several features includ-
ing the presence of four conserved cysteine residues and
“vertical” receptor signal transduction. These receptors often
promote rapid and reversible changes in cellular metabolism
or migration, in contrast to “horizontal” cytokines receptors
which usually cause slower and irreversible cellular changes,
such as proliferation and apoptosis [2, 3]. Members of the
chemokine family are divided into four groups depend-
ing on the spacing of their first two cysteine residues:
CC chemokines, which have two adjacent cysteines, CXC
chemokines, with the two cysteines separated by one amino
acid, C chemokines, characterized by the presence of only
two cysteines, and CX3C chemokines with three amino acids
separating the initial pair of cysteines.
Among the fifty-two chemokines [4] discovered to date,
nineteen are presently considered to be relevant in heart dis-
ease, seven of them belonging to the class of CC chemokines,
ten to the CXC family, one to the CX3C chemokines, and one
to C chemokines.
Some chemokines play a role in the early stages of cardio-
vascular disease like atherosclerosis or acute ischemia [5–9].
Others are involved in both early and late response to injury
and are strongly associated with cardiac arrhythmias, heart
failure, and chronic rejection of a transplanted heart [10–22]
(Figure 1). The chemokines associated with cardiovascular
disease discussed in the present review are listed in Table 1.
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Chemokines at different stages of cardiovascular diseases
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Figure 1: Association between chemokines and pathological conditions present in cardiovascular diseases. Some chemokines play a role in
the early stages of cardiovascular disease, being associated with atherosclerosis and acutemyocardial ischemia. CCL2 andCXCL8 are involved
in both early and late response to ischemic injury, recruiting leukocytes after acute ischemia and playing a role in heart failure. Moreover,
together with other chemokines, they are strongly associated with cardiac arrhythmias, a dangerous event which may occur at all stages of
the disease. Finally, there are chemokines frequently found in the late response to injury and in the repair process and chemokines more
associated with dilated cardiomyopathy and chronic rejection of a transplanted heart.
2. Cardiovascular Disease, from Ischemia to
Heart Failure
Myocardial ischemia (MI) is a state of myocardial impair-
ment due to an imbalance between the level of coronary per-
fusion and myocardial energy demand. Although atheroscle-
rosis is a central part of cardiovascular disease, reviewing the
role of chemokines in its development is beyond the scope
of the review. We will discuss chemokines involvement in
cardiovascular disease from the first event which changes
dramatically the metabolism and the homeostasis of the
heart, that is, myocardial ischemia.
The mechanical work of the myocardium is driven by
aerobic metabolism, which produces energy in the form
of adenosine triphosphate (ATP). Myocardial ischemia is
followed by the progression from reversible to irreversible
myocardial cell injury within about thirty minutes. After this
period, histologic features of coagulation necrosis appear,
with nuclear pyknosis, karyolysis, and exudative inflam-
mation. Sudden death of the whole heart as such does
not occur; every cell of the heart singularly responds to
the injury (ischemia) and to the removal of the injury
(reperfusion) with biochemical changes moving toward life
or death (Figure 2). The severity of the damage depends on
time, on the coronary artery involved, and on the entity of the
inflammatory response. Two different scenarios are possible
after ischemia: permanent occlusion or reperfusion. In case
of permanent occlusion, potential causes of irreversibility
are catabolism without new synthesis of macromolecules,
reduced transmembrane gradients of Na+ and K+, Ca2+ over-
load, catabolite and oxygen radicals accumulation, enzyme
denaturation, cell swelling, andmembrane rupture [23]. Early
reperfusion, on the other hand, is associated with rapid
cellular infiltration of neutrophils and monocytes mainly
into the jeopardized border zone surrounding the infarcted
area [24]. Neutrophils migrate from the perivascular area
and remain primarily in the border zone whereas monocyte
migration into the infarct proceeds very rapidly [25–27]. A
possible evolution of both scenarios is cardiac hypertrophy,
a thickening of the ventricular walls in the heart, which is
an adaptive response to pressure overload, volume stress,
mutations of proteins involved in the structure or loss of
cardiomyocytes, and contractility, all possible consequences
of myocardial ischemia. Hypertrophy can be physiological,
present as normal response to healthy exercise, characterized
by a concentric aspect, or pathological, leading to remodeling
and changes in the shape and structure of the myocardium.
Concentric hypertrophy is believed to have a compensatory
function by diminishing wall stress and oxygen consumption
[28] whereas pathological hypertrophy can lead to heart
failure (HF) and is associated withmajor arrhythmias. Patho-
logical hypertrophy activates the expression of genes related
to collagen, chemokines, and actin which are not stimulated
by physiological hypertrophy [29]. Myocardial hypertrophy
is associated with persistent inflammation, irrespective of the
cause of the disease. Indeed a similar pattern of inflammatory
activation is present in patients with aortic valve stenosis
or MI, as well as in animals subjected to different stimuli
leading to the development of pathological hypertrophy [19,
30–32]. At the cellular level, cardiomyocyte hypertrophy is
characterized by an increase in cell size, enhanced protein
synthesis, and heightened organization of the sarcomere
[33]. This pathological condition is associated with fibrosis
development, characterized by monocytes infiltration and
activation of matrix-metalloproteinase (MMP) in extracel-
lular matrix (ECM). In animal models, profibrotic genetic
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Figure 2: Metabolic changes triggered by ischemic insult and possible evolutions of the injury with the crosstalk between chemokines. The
pH decrease, provoked by ischemia, is the event turning on the process. The cell membrane is damaged and debris activates the classic
complement pathway in the infarcted myocardium. ROS, adenosine, and complement activate mast cells to produce TNF and histamine,
leading to leukocyte recruitment from the vessels. Depending on the presence or the absence of reperfusion, there is a different crosstalk
between chemokines, aimed at restoring the balance. Dysregulated or exaggerated responses may actually lead to a progression of the disease
(see text for details, chemokines in red).
pathways are activated early, before hypertrophic remodeling
[36]. Myocardial fibrosis is a hallmark of hypertrophic car-
diomyopathy and can evolve in decompensated remodeling,
with myocytes slippage and wall thinning [37, 38]. If the loss
of viable myocardium has been massive, wall stress increases
further and the final result can be left ventricular (LV) dilation
and HF a condition in which cardiac function is seriously
impaired. This vicious “circle” results in increased blood
pressure and LVmechanical overload, which further worsens
the condition.
Chemokines seem to act as a “working-network” instead
of a “one chemokine-one function” way, in modulating this
cardiac response to injury. This characteristic is well known
in the field of immunology and is one of the causes of the
typical redundancy seen in several inflammatory processes.
The complexity of this network is far from being completely
understood and described, but recent studies are trying to
reassemble the pieces of the puzzle. Recently [39] a small
clinical study for risk stratification (a tool for identifying and
predicting which patients are at high risk of cardiovascular
events) performed in patients after MI evaluated the prog-
nostic significance and the clinical relevance of a cluster of 27
serum cytokines, including the chemokines CXCL8, CCL11,
CCL2, CCL3, CCL4, and CCL5. The authors did not identify
a single inflammatory cytokine capable of predicting adverse
events in a long term follow-up, but they suggested that the
presence of more than 13 cytokines above the median value
was useful for risk stratification. Another clinical study [40]
enrolled 28 patients undergoing PCI, 20 undergoing coronary
angiography, and 28 healthy controls, with the aim of ana-
lyzing the plasma levels of CCL2 and CCL11 in all groups.
The results showed a significant increase of both CCL2 and
CCL11 in patients suffering heart disease as compared to
healthy subjects. Moreover, the plasma levels of the two
chemokines rose significantly after PCI; notably CCL2 rose
after 3 and 6 months following PCI and CCL11 rose 24 h but
not 3months after PCI.When the process degenerates toward
failure, the inflammatory pathway appears to be almost the
same irrespectively of the initial cause of pathology.
Some of the most common signaling pathways [41],
relevant in the crosstalk between innate immune response
and ischemic heart, include the following:
(i) TLR-4, responsible for macrophage homing and
inflammatory cytokine production;
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(ii) HMGB1/TLR-4 for monocytes recruitment and acti-
vation of CXCL12-CXCR4 pathway in the leukocytes;
(iii) gp130/JNK/STAT3 and TLR-4/myD88/CAMKII/NF-
𝜅B for monocytes and monocyte/neutrophils recruit-
ment and activation;
(iv) cGMP/eNOS, throughCXCL12-CXCR4 axis, for neu-
trophils recruitment and matrix remodeling after
ischemic injury.
These pathways underline the presence of communication
between cardiovascular and immune systems through several
mediators including chemokines. Therefore, we will discuss
in detail their role in the progression from ischemia to heart
failure.
2.1. CCL2, CCL3, CCL4, and CXCL2. CCL2 (Monocyte Che-
moattractant Protein or MCP-1) has been the subject
of numerous investigations in the field of cardiovascular
research. It is produced by a variety of cells including
macrophages, fibroblasts, and epithelial and endothelial cells
[10, 42] and it is thought to play a key role in several
pathophysiological processes, such as atherosclerosis and
remodeling after MI. In a large cohort of patients with acute
coronary syndrome, an elevated baseline level of CCL2 was
associated both with traditional risk factors for atheroscle-
rosis and with an increased risk for death or MI [43]. CCL2
was found to increase in the rat heart during reperfusion but
not after 1 or 2 hours of permanent infarction [44]. It was
also detected in human cardiac myocytes and human cardiac
fibroblasts which revealed CCL2 production under cytokine
stimulation, but not under hypoxia, in vitro [45]. In patients
with ischemic cardiomyopathy, polymorphism in CCL2 gene
(CCL2-2518 A/G single nucleotide polymorphism) was cor-
related with C-reactive protein (CRP) level [46]. Altogether
these findings suggest that this chemokine is more associ-
ated with inflammation than with hypoxia/ischemia, being
strongly regulated by reperfusion and correlated with a
known inflammatory marker such as CRP.
To investigate themechanismof action ofCCL2 and other
chemokines in the myocardial response to injury, several
preclinical studies were performed in the last two decades.
Entman, Frangogiannis, and their coworkers extensively
explored this topic and unveiled the connection between
CCL2 and cardiac fibrosis in a mouse model of ischemia
without necrosis [47]. In particular CCL2, identified in
the ischemic myocardium after repetitive cycles of brief
ischemia/reperfusion (IR), was associated with increased col-
lagen content, macrophages infiltration, interstitial remodel-
ing, and LV dysfunction, phenomena which were attenuated
in CCL2−/− mice. Moreover, fibroblasts isolated from Wild
Type (WT) mice exposed to repetitive IR exhibited increased
proliferative capacity, which was abrogated in fibroblasts
from CCL2 null-hearts. It was found that the profibrotic
actions of CCL2 are probably associated with decreased
macrophage recruitment since at a molecular level no altered
expression of genes associated with cardiac fibrosis was
observed. In a different study, using the same experimental
model [6], same group also discovered that reactive oxygen
species generation in the reperfused myocardium rapidly
induced CCL3, CCL4, and CXCL2 upregulation in the venu-
lar endothelium in the absence of infarction or irreversible
cellular injury. In this study, the chemokines induction cor-
related with nuclear translocation of NF-𝜅B, c-Fos, and c-Jun
in cardiac venules. Since angiogenesis begins in the venular
endothelium, these experiments could indicate a potential
role of chemokines as angiogenetic agents during a transient
ischemia without necrosis. Interestingly, Tarzami and col-
leagues found a protective effect of CXCL2 dependent CCL2
expression in cardiac ischemia without reperfusion, a sur-
vival pathway in target cardiac myocytes themselves. Indeed,
CCL2markedly decreased hypoxia-induced cell death in cul-
tured cardiacmyocytes [35]. Among chemokinesmodulating
these processes, CCL2 and its receptor CCR2 seem to be one
of the keys of the shift from physiological to pathological
conditions in both heart and vessels. CCL2 chemotactically
attracts mononuclear cells which are source of fibrogenic
mediators like TGF-𝛽 and Fibroblast Growth Factor. In
addition, it inducesmacrophage synthesis of TGF-𝛽1 and col-
lagen. CCL2 is also reported to directly modulate fibroblast
activity and phenotype. Moreover, it may be an important
mediator in the recruitment of fibroblast progenitors [11].
Activation of the CCL2/CCR2 pathway induces mono-
cyte-mediated inflammation and several related processes;
enhanced CCR2 fluorescence intensity on monocytes was
observed in hypertensive patients as well as in rat models. In
CCR2−/− mice, Angiotensin II- (Ang-II-) induced vascular
inflammation and remodelingwere blunted compared toWT
animals; in a model of fibrosis and hypertrophy secondary
to suprarenal aortic constriction, chronic treatment with an
antibody against CCL2 led to myocyte hypertrophy without
fibrosis and to an improvement in diastolic dysfunction, in
the absence of an effect on blood pressure or systolic function.
In contrast, control rats showed hypertrophy and reactive
fibrosis [48, 49]. Ang-II infusion is a well-established
model of myocardial hypertrophy and it has been used
to characterize chemokine expression and cellular element
involvement. Kuwahara and colleagues showedmRNA-CCL2
upregulation from day 1 to day 3 after treatment, followed
by TGF-𝛽 induction at day 3 to day 28 [49]. The results
were confirmed by Sopel and colleagues who measured
chemokines expression using quantitative Real Time PCR.
They also showed that fibrocytes (fibroblast progenitor cells)
were recruited into themyocardiumprior to the development
of myocardial fibrosis and were probably recruited out of
the circulation by gradients of CXCL12, CCL21, and CCL2
[50]. A further demonstration of CCL2 involvement in the
progression from hypertrophy to fibrosis originates from
a model of genetic deletion of CCL2 in mice [51]. CCL2-
Knock-Out (KO) animals receiving infusion of Ang-II were
prevented from fibrosis development, induction of collagen,
induction of TGF-𝛽1, and TNF mRNA expression. In this
model, the nonadaptive hypertrophy in the heart clearly
required CCL2 induction. In this regard, an interesting
clinical study [52] found that patients with heart failure had
higher level of circulating CCL2 as compared with healthy
controls despite treatmentwith a high-dose of ACE-inhibitor.
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On the other hand, angiogenic and cardioprotective
effects of CCL2 have also been reported [35], suggesting
distinct effects of this chemokine on remodeling after MI.
Morimoto and colleagues investigated the effect of cardiac
CCL2 overexpression on LV dysfunction and remodeling in
a murine model of MI [53]. The interesting findings were
that cardiac overexpression of CCL2 reduced infarct area and
scar formation improving LV dysfunction and remodeling,
thus suggesting a controversial role of CCL2 in response to
MI. At the same time Dewald and colleagues [54] found
that inhibition of CCL2 could have the same deleterious
effect observed with corticosteroid treatment in patients
with MI [55], that is, impairing the repair processes, after
injury. Altogether, the role of CCL2 appears therefore to go
beyond the simple recruitment/proinflammatory effect and is
clearly involved in the fine and critical modulation of cardiac
homeostasis after a detrimental insult.
2.2. CCL5. Recently, two studies showed the effects of
chemokine inhibition on MI. In the first work [7], treat-
ment with a monoclonal antibody anti-CCL5 (RANTES)
significantly reduced both infarct size and postinfarction HF
in a murine model which was correlated with a decreased
leukocyte recruitment within the infarcted hearts. In the
second study [9], mice subjected in vivo to left coronary
artery permanent ligation and followed up for different times
(up to 21 days) showed a beneficial reduction in infarct
size as compared to controls when treated with chemokine
inhibitors, in particular with CCL5 inhibition, which reduced
cardiac injury/inflammation and improved survival. This
treatment was associated with a decrease in postinfarction
myocardial leukocyte infiltration, reactive oxygen species
release, and circulating levels of CXCL1 and CCL2.
2.3. CXCL8, CXCL1, and CXCL5. CXCL8 (IL-8) is a
chemokine attracting neutrophils, which plays a key role
in the early phase of reperfusion injury as well as in heart
failure. CXCL8 expression was found to increase in ischemic
reperfused myocardium suggesting a role in neutrophil-
induced myocardial injury by promoting ligand-specific
adhesion to cardiac myocytes [12]. Damås and colleagues
showed that circulating levels of CXCL8, CXCL1 (GRO-𝛼),
and CXCL5 (ENA-78) gradually increased in patients with
congestive heart failure (CHF) in parallel with an increase
in NYHA functional class [15, 56]. Recently [57], high levels
of CXCL8 in patients suffering ST elevation myocardial
infarction, complicated by HF, were associated with less
improvement in LV function during the first 6 weeks after
PCI, suggesting a possible role of CXCL8 in the reperfusion-
related injury. In 2001, Chandrasekar and colleagues found
that myocardial IR in the rat activates NF-𝜅B and induces
neutrophil infiltration via a homologous of CXCL8 in rats
called LIX (lipopolysaccharide-induced CXC chemokine)
[13]. LIX was found to be expressed by resident myocardial
cells during IR and induced in cultured cardiomyocytes by
oxidative stress or TNF-𝛼 via NF-𝜅B activation. Moreover,
in a further study, they discovered that LIX, in addition
to attracting and activating neutrophils, also amplified
the inflammatory cascade, stimulating local production
of cytokines that had negative inotropic and proapoptotic
effects [58].
Damås and colleagues [15] examined the circulating levels
of CXCL8, CXCL1, and CXCL5 in patients with various
degrees of HF, finding that they had a significant increase in
the levels of all three chemokines and that both CXCL8 and
CXCL1 correlated with the NYHA class.
2.4. CXCL12. An additional chemokine involved in cardiac
hypertrophy and remodeling is CXCL12, also known as
stromal cell-derived factor 1 (SDF-1). This chemokine has
a key role in hematopoiesis, cardiogenesis, vasculogenesis,
and neurogenesis [59]. The increased expression of CXCL12
in ischemic tissue is considered a beneficial signal attracting
stem cells into the heart [17]. Its involvement in cardiovascu-
lar homeostasis has been described by several studies.
The main receptor for CXCL12 is CXCR4 which is
expressed in several cells including those from megakary-
ocytic lineage [60].Themain function of CXCL12 interaction
with CXCR4 is the mobilization of stem cells from bone
marrow.
LaRocca and colleagues [61] demonstrated that CXCR4
physically interacts with the 𝛽2 adrenergic receptor and
modulates the subsequent downstream signaling. CXCL12/
CXCR4 are expressed on cardiac myocytes and inhibit con-
tractility in response to the 𝛽-adrenergic receptor agonist,
isoproterenol. Recently [62], it was reported that CXCR4
expression prevented cardiac hypertrophy induced by iso-
proterenol: CXCR4-KO and WT mice were subjected to
chronic administration of isoproterenol for 3 weeks; bio-
chemical as well as echocardiographic and hemodynamic
measurements were performed. KO mice showed worsened
fractional shortening and ejection fraction as compared with
WT animals, as well as upregulation of apoptoticmarkers and
reduced mitochondrial function. There was also an increase
in myocardial fibrosis. A CXCR4 gene transfer performed in
KO animals reduced apoptosis and improved mitochondrial
and cardiac function. However, controversies exist over the
protective versus harmful effects of CXCL12 and CXCR4 in
models of cardiac injury. Chu et al. [63] found that CXCL12
is constitutively secreted by cardiomyocytes and upregulated
by Ang-II and reported an increase in fibroblast migration
in a mouse model of dilated cardiomyopathy, suggesting a
profibrotic role of this chemokine in the chronically failing
heart. In contrast, two authors [64, 65] reported that the
CXCL12/CXCR4 axis was the mechanism of the protective
effect of apelin-13, an isolated bioactive peptide from bovine
extract, and of erythropoietin (EPO), respectively. Apelin-13
increased angiogenesis and cardiac repair by the upregulation
of CXCL12/CXCR4 and homing of vascular progenitor cells.
EPO, known for its protective properties after IR injury
[66], attenuated remodeling, enhanced neovascularization,
and diminished apoptotic cells in the peri-infarct area 6 and
30 days after permanent infarction.Moreover, EPO treatment
mobilized bone marrow-derived stem cells (BMCs) and
enhanced homing of Sca1(+) and CXCR4(+) BMCs toward
a CXCL12 gradient into the ischemic myocardium. Inter-
estingly, EPO had no beneficial effects on resident cardiac
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stem cells. Finally, in an interesting work [67], Hwang and
Kloner investigated the potential benefit of simultaneous
administration of multiple soluble factors (SFs), including
CXCL12𝛼, in rats subjected to permanent coronary ligation.
The rationale of this work was based on the knowledge that
in the clinical setting [68] delivery of a single SF to the
ischemic heart had limited effects. Their results revealed no
enhancements in cardiac function or reduction in infarct size.
Among the possible explanations for the negative results, the
authors reported that coronary artery occlusion might have
prevented access of intraperitoneal administered SFs to the
ischemic region of the myocardium.
2.5. CXCL13 and CXCL16. Waehre and colleagues [18] stud-
ied the chemokines associated with alteration of the structure
in extracellular matrix (ECM), in particular with the func-
tion of SLRPs (Small Leucine-Rich Proteoglycans) proteins.
SLRPs are proteins capable of binding various types of
collagens regulating kinetics, assembly, and spatial organi-
zation of fibrils. They found that the interaction between
CXCL13 and its receptor CXCR5 was involved in myocardial
remodeling, probably regulating proteoglycans and quality of
myocardial ECM.This interaction was found to be protective
since genetic deletion of the receptor CXCR5 exacerbated
dilatation and increased mortality, probably via lack of the
increase of SLRPs.
Moreover, in a model of pressure overload dependent
right ventricle remodeling, they found [19] that CX3CL1
(also known as fractalkine), CCL5, and CXCL16 regulated
expression and posttranslational modifications of SLRPs in
cardiac fibroblasts. Therefore these inflammatory mediators
may play a role in the development and progression of right-
sided myocardial remodeling during pressure overload.
2.6. CX3CL1 and XCL1/2. Recently, two chemokines were
found to be associated with HF, namely, CX3CL1 and XCL1/2
(also known as Lymphotactin). CX3CL1 is a chemokine with
a polypeptide structure different from the typical structure
of other chemokines and represents the only member of the
CX3C group. It was found to be an independent predictor
of mortality in patients suffering HF [69]. Its expression is
modulated by TNF-𝛼 [70] and it is thought to promote car-
diac injury and HF by activating MAPKs pathway (mitogen-
activated protein kinases pathway) [21]. In a rat heart trans-
plant model, both CX3CL1 and XCL1/2 were found to be
involved in the rejection of transplanted hearts secondary to
cytomegalovirus infection [22]. The authors suggested that
rejection was due to an increase in vascular infiltration of
inflammatory cells in the graft through enhanced chemokine
expression.
2.7. CCL21. CCL21 is a chemokine involved in tissue remod-
eling and described as “homeostatic” chemokine. Its concen-
tration in serum fromHFpatients was higher than in controls
and was independently associated with mortality in chronic
and acute post-MI HF. Interestingly, mice lacking CCL21
receptor, CCR7, showed improved survival and attenuated
increase inmarkers ofmyocardial dysfunction andwall stress
in post-MIHF after 1 week [71] but in the long term presented
myocardial dysfunction and increased wall stress. Repair
for recovery or decompensated remodeling appears like a
crossroad for mediators involved in the process and it is not
clear which “input” could tilt the balance in favor of recovery.
The autonomic nervous system (ANS)may play a critical role
in this setting.
3. Crosstalk between Chemokines and
Autonomic Nervous System
Thebest definition for the crosstalk between innate immunity
and autonomic nervous system is likely to be allostasis, that
is, maintaining stability through change [72]. The signals
travelling throughout the body create a network of informa-
tion fine-tuned by the incessant dialog between the systems,
aimed at directing the necessary mutual changes. During the
late nineties, Armour and colleagues [73] identified intrinsic
cardiac ganglia in the heart, especially in the posterior
surface of the atria and superior surface of the ventricle,
and showed that processes occurring in such an intrinsic
cardiac nervous system involve afferent neurons, local circuit
neurons, and both sympathetic and parasympathetic efferent
postganglionic neurons [74].
When an injury occurs, the heart signals the damage
to the nervous system, which responds by leading an orches-
trated reaction involving neurohormones, chemokines, cy-
tokines, neuropeptides, and other mediators. After MI, sen-
sory afferent neurons, which respond to hypoxia-induced
changes in the heart, are also responsible for pain perception
[75] and the sympathetic nervous system modulates activa-
tion/proliferation of progenitor cells from bone marrow [76–
78].
It is becoming increasingly clear that there is both plastic-
ity and integration at many peripheral anatomical sites in the
cardiovascular-immune-neural axis: innate immune system
stimulates autonomic nervous system through cytokines,
chemokines, platelet-activating factor, and arachidonate
metabolites released from immune cells and this activation is
integrated at the hypothalamic level [79–82]. Mutually, sym-
pathetic system [83], through the release of norepinephrine
(NE), can modulate the functions of immune system cells
through receptors expressed on their surface. Other peptides
like Neuropeptide Y (NPY) and Substance P (SP) colocalize
with NE or are associated with its function and were found to
be relevant to heart disease.
SP is a neuropeptide belonging to the family of tachykin-
ins, widely distributed in the nervous system, including the
stellate ganglia. It is also localized in the heart and released
by sensory nerve endings and immune cells. Macrophages
and neutrophils are found to express preprotachykinin gene-I
(PPT-I) mRNA and are modulated by SP biological actions.
In the emerging role of chemokines, CXCL2, CCL3,
CCL2, and CXCL12 seem to be involved in the crosstalk with
the ANS and organs.
In an in vitro model using isolated primary mouse neu-
trophils, SP primed neutrophils for chemotactic responses to
the chemokines CXCL2 and CCL3 and induced both mRNA
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and protein expression of CCL3 and CXCL2 in neutrophils
and upregulated the chemokine receptors CC chemokine
receptor 1 (CCR1) and CXC chemokine receptor 2 (CXCR2)
[84].
In a recent study it was found [85] that SP seems also to act
as a “primer” for cardiac fibroblasts, transiently upregulating
genes related to ECM regulation and proteins rather than
directly converting fibroblasts to myofibroblasts or increas-
ing collagen synthesis. Moreover, in CD34+-derived human
mast cells [86], production of CCL2, the potent profibrotic
chemokines, was significantly increased by SP treatment,
both at protein and at mRNA level. Interestingly vagal nerve
stimulation (VNS), which decreases infarct size and adverse
LV remodeling and HF in several experimental models,
suppressed SP in a rat model of cardiac ischemia [87] and
decreased CCL2 and LIX plasma levels in the rat after IR
injury [88–90].
CXCL12 seems to be involved in the remodeling of
stellate ganglion neurons, a phenomenon occurring in several
cardiomyopathies [91–95]. After MI, neural remodeling was
associated with an increase in NPY immune-reactivity [96];
NPY, like SP, is a neuropeptide colocalized and coreleased
with NE from sympathetic nerve terminals. Wang and
colleagues [97] showed that remodeling after MI could be
reversed with a therapy combining NPY and mesenchymal
stem cells (MSC) in a rat model of MI through a NPY
dependent upregulation of CXCL12 gene and others required
for mitosis in MSC.
Finally, it was very recently demonstrated [98] that a
potent neurotrophin, nerve growth factor (NGF), attracted
human bone marrow-derived mononuclear cells similarly to
what was observed with CXCL12, used as positive control.
In this model NGF promoted progenitor cells homing from
the bonemarrow to the infarcted heart improvingmyocardial
blood flow and cardiac function.
The interaction between parasympathetic system and
innate immunity has been clarified byTracey at the beginning
of this century [99] with the discovery of cholinergic anti-
inflammatory pathway, an axis of neuroimmune modulation
where acetylcholine (ACh),𝛼-7nAChR, andmacrophages are
the main players with anti-inflammatory properties. When
activated, this pathway protected organs, including heart,
from the consequences of the ischemic injury [89, 90, 100,
101], decreased levels of CCL2 and LIX after reperfusion
injury [88], and downregulated the expression of CCL2,
CCL4, CCL5, CCR1, CCR2, and CCR5 in murine autoim-
mune myocarditis [102].
Both these pathways, immune-sympathetic and immune-
parasympathetic, are involved in the beginning and in the
progression of heart disease and are reciprocally connected,
affecting and modulating each other’s functions. It is becom-
ing evident that the mutual crosstalk within the autonomic
nervous system between sympathetic and parasympathetic
fibers is represented by the ability to reciprocally modulate
neurotransmitters release [103] and that thesemolecules have
the ability to modulate the innate immune response.
Despite these intriguing hints, to our knowledge the
mutual effects of chemokines, Substance P, NPY, NGF, and
ANS in the progression of heart disease remain largely
unknown.
It is increasingly clear that the individual autonomic
responses already characterized before the development of
cardiovascular disease could determine the outcome and the
progression of cardiac dysfunction [104–107]. It is conceiv-
able that ANS activation, through neurotransmitters, neu-
rotrophins, and immune mediators, could act as a primary
imprinting which orchestrates the response to injury in sense




The heart is a highly innervated organ and the link between
the autonomic nervous system and ventricular arrhythmias is
universally acknowledged: an increased sympathetic tone is a
trigger for arrhythmic events in several conditions including
patients with ion-channel diseases, ischemic heart disease,
and HF. Although the knowledge of inflammation role in
the context of cardiac arrhythmia diseases is still scanty,
some evidence suggesting its contribution in favoring an
arrhythmogenic substrate has been provided.
One of the most intriguing hypotheses is that inflam-
matory mediators may have a direct effect on the electrical
properties of cardiomyocytes. This hypothesis is in agree-
ment with the finding that cytokines and chemokines act
as modulators of excitability in neurons [108]. Left cardiac
sympathetic denervation (LSCD) is an established additional
treatment for patients with long QT syndrome (LQTS)
and catecholaminergic polymorphic ventricular tachycardia
(CPVT) nonprotected by 𝛽-blocker (BB) therapy [109, 110].
The presence of inflammatory activity in stellate ganglia of
genetically confirmed LQTS and CPVT patients, who under-
went LSCD because of malignant ventricular arrhythmias
resistant to BB therapy, was evaluated by Rizzo et al. [111].
Inflammatory infiltrates composed of T lymphocytes and
macrophages anddegeneration of adjacent ganglion cells sug-
gestive of chronic ganglionitis were found in all LQTS/CPVT
patients as compared to none of ten control subjects who died
in accidents.They proposed that T cell-mediated cytotoxicity
toward sympathetic ganglionic cells may increase adrenergic
firing and enhance electrical instability in patients already
genetically predisposed to ventricular arrhythmias.
A very recent study identified a chemokine that can
influence electrical stability and directly modulate action
potential duration (AP): CXCL9 has been shown to shorten
cardiac AP by reducing sarcolemmal L-type Ca2+ current
via the G protein-coupled receptor CXCR3, in LV myocytes
isolated frommalemice [112]. Also in the context of common
cardiac diseases such as MI, a proinflammatory condition
seems to be associated with an increased risk of developing
life-threatening arrhythmias. Elmas and colleagues [14] stud-
ied the levels of matrix-degrading metalloproteinases, their
inhibitors (TIMPs), andCXCL8, the predominant chemokine
interacting with them, in patients with MI complicated or
not by ventricular fibrillation (VF). Levels of TIMP-1 and
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CXCL8 were found to be significantly higher in patients
with MI complicated by VF as compared to MI patients
without VF. Since high TIMP levels are related to the degree
of fibrosis which is a substrate for electrical instability, the
presence of these circulating inflammatory mediators may
contribute to the occurrence of VF. In addition CXCL8 is
a powerful chemoattractant responsible for the recruitment
of neutrophils; the adhesion of neutrophils to ischemic
cardiomyocytes may result in excitation-contraction distur-
bances and development of arrhythmias in inflamed cardiac
tissue. A high degree of fibrosis is also documented in
arrhythmogenic ventricular cardiomyopathy (ARVC), a heart
muscle disease characterized by fibrofatty replacement of the
right and, less frequently, of the left ventricle. The presence
of elevated levels of serum inflammatorymediators including
CXCL8, IL-6R, CCL2, and CCL4 and an altered balance
between circulating proinflammatory and anti-inflammatory
factors have been found in patients with ARVC compared to
controls [113].The same study additionally showed that some
inflammatory molecules, either circulating or derived from
themyocardium,may lead to disruption of desmosome struc-
ture through dislocation of plakoglobin from desmosomes
to intracellular space, myocyte injury, and arrhythmogenesis
[113].
There is growing evidence of chemokine mediators in-
volvement also in the context of atrial fibrillation (AF).
To elucidate the role of circulating inflammatory factors
in atrial fibrillation, Wu et al. conducted a meta-analysis
based on observational studies [114] and evidenced that the
presence of increased inflammation molecules (CRP, IL-6,
and TNF-𝛼) was significantly associated with a greater AF
risk in the general population. High levels of CRP, CCL2,
and CXCL8 among patients with AF were found by several
investigators [115, 116]. Notably, elevated levels of CXCL8
detected in patients with permanent AF but not in patients
with paroxysmal AF suggested a link between low-grade
inflammatory reaction and long-lasting AF [116].
The West Birmingham Atrial Fibrillation Project dis-
closed in a large cohort of AF patients the independent
correlation between low plasma levels of CX3CL1 and low
risk of major cardiovascular events [117]. Although these
studies on AF are only observational and do not explain
the molecular mechanisms linking inflammation with AF
risk, they suggest the assessment of plasma concentrations
of chemokines as a potential application to improve the risk
stratification in AF patients.
The presence of inflammatory chemokine mediators
appears to be associated with an increased arrhythmic risk
both in patients affected by inherited cardiac diseases and in
patients with high degree of fibrosis due to nongenetic causes.
Inflammatory molecules are significantly more prevalent
in patients with heart diseases and documented cardiac
arrhythmias than in patients free of arrhythmia. It is likely
that in most cases inflammation may act as a trigger in
subjects already susceptible to developing arrhythmia.
It must be mentioned that it has not been conclusively
shownwhether the inflammatory component plays a primary
pathogenic role or whether it is rather the consequence of the
myocyte injury. The fact that many studies showed ongoing
active inflammation in a symptom-free time, remote from
any acute event, suggests inflammation may be a trigger
of arrhythmia for already susceptible subjects. However,
further efforts are required to elucidate the specificmolecular
mechanisms involving chemokines and other inflammatory
mediators in the development of cardiac arrhythmia.
5. Chemokines and Dilated Cardiomyopathy
Dilated cardiomyopathy (DCM) is amyocardial disease char-
acterized by an increase in LV size and volume with normal
LV wall thickness, associated with a progressive decline of LV
contractile function leading to HF [118]. Being the third most
common cause of HF worldwide, DCM is the underlying
disease leading to up to 25% of CHF cases in the US [119]
and the most common cause of heart transplantation. With
a prevalence of 1 : 2500, DCM is a common and largely irre-
versible form of heart muscle disease. Familial cases account
for about 20–35% of all DCM and have been reported linked
to a diverse group of >20 loci and genes. Although a specific
cause for the disease is found in almost 30–35% of DCM
cases the others receive an exclusion diagnosis, idiopathic
dilated cardiomyopathy (IDC) [120]. Multifactorial genetic
traits [121, 122], associated with persistent viral infection and
immunological abnormalities including autoimmunity [123],
have been postulated as potential causes in the pathogenesis
of IDC since the late 1980s. Experimental and clinical data
suggest a causal relationship between myocarditis and IDC,
confirming that a chronic inflammatory processmay underlie
the development of IDC [122]. Being the most frequent
cardiomyopathy phenotype, DCM appears to be the final
common pathway ofmany cardiac injuries. It appears that the
pathways involvedwith this condition tend to bemore disease
specific in the initial phases of myocardial injury, but they
involve progressively more stereotyped mechanisms in the
later phases of myocardial remodeling, progressively leading
to DCM and heart failure [124].
Several sources including the natural history of patients
with particular conditions such as Chagas disease provided
a strong evidence of the process leading from myocardial
inflammation to dilated cardiomyopathy [118]. Chagas dis-
ease is a well-characterized example of how the immune
response meant to avoid the dissemination of Trypanosoma
cruzi, the parasite responsible for the disease, results in the
development of a potentially fatal cardiomyopathy in 30%
of the infected cases, years after the acute infection [125].
In the context of this disease, T. cruzi triggers an innate
immune response involving the production of cytokines (IL-
1, IL-6, and TNF-𝛼), chemokines (CCL2, CCL5, andCXCL9),
and an adaptative Th1 T cell lymphocyte/antibody response.
This response leads to control but not to elimination of the
infection, causing the progressive development of Chagas
cardiomyopathy resulting from this sustained inflammation
in susceptible individuals [126]. These susceptible subjects
have been identified as patients showing a smaller T reg lym-
phocyte compartment producing IL-10 and IL-17, resulting
in a deficient suppressive activity leading to uncontrolled
production of Th1 cytokines and, among others, of the
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chemokines CCL2, CCL5, and CXCL9 [127, 128]. Several
recent studies supported this finding, demonstrating that
gene polymorphism associated with increased or decreased
production of the above-mentioned chemokines exerts favor-
ing or protective effects, respectively, on the development of
Chagas cardiomyopathy [20, 129, 130].
Chemokines causing leukocyte infiltration and cytotoxi-
city were investigated as potential mechanisms of cardiomy-
ocyte damage also in chronic myocarditis and in sporadic
IDC. Macrophages appear to be one of the key cells causing
cardiac myocyte damage; CCL2 and other chemokines are
a major signal for the recruitment and activation of mono-
cytes/macrophages. In 1995 Seino et al. reported for the first
time that the CCL2 mRNA is expressed in the myocardium
of patients with IDC [131]. Shortly after, Kolattukudy and
colleagues demonstrated in a transgenic murine model that
CCL2 leads to increased myocardial leukocyte infiltration
and to the phenotype of dilated cardiomyopathy [132].
Therefore, since the late 1990s, CCL2 has been known to be
dynamically regulated in DCM and to possibly contribute to
the deterioration in LV function [133]. In 2007 the group of
Ohe confirmed that the expression of CCL2 was present in
all myocardial samples from each of the 13 DCM patients
analyzed in their study, but not in those from control subjects.
Moreover, the expression level of CCL2 in the myocardium
was correlated with the degree of impairment of cardiac
function [134]. These experiments proved once more that
augmented expression of specific chemokines was associated
with adverse ventricular remodeling with their homeostasis
with the maintenance of cardiac structure and function.
Finally, Göser et al. [135] found that the same chemokines
CCL2 and CCL3, acting through their receptors CCR2 and
CCR5, are key chemokines for the development of experi-
mental autoimmune myocarditis and proved that inhibition
of CCL2 with 7ND gene transfection significantly reduced
disease severity in an experimental model of autoimmune
myocarditis. However, CCL2 does not exert only unfavorable
effects on the dilated failing heart. Interestingly, it may induce
also stem cells homing in the dilated myocardium, thus
proving that chemokine signaling may be a useful adjuvant
for stem cell therapy [136].
Altogether, these experiments show the important role of
chemokines, especially of CCL2, in dilated cardiomyopathy
and also in myocarditis, providing further clues supporting
the existence of a common inflammatory pathway leading to
the dilated cardiomyopathy phenotype. Furthermore, some
experiments carried out in animal models of autoimmune
heart inflammation showed a favorable response in terms
of reduction of inflammatory T cells infiltration and car-
diomyocyte damage following the administration of some
chemokines (e.g., CXCL1, acting through toll-like-receptor 4)
[137].
These results show that further knowledge of the mech-
anisms underlying the chemokine network may be useful to
understand the pathophysiological basis of a broad range of
conditions leading to DCM and thus to favorably influence
the inflammatory conditions underling this widespread heart
disease.
6. Chemokines in Clinical Practice: A New
Tool to Stratify Cardiovascular Risk?
The parameters used to stratify the risk come from clinical
practice and from laboratory results. The prediction of the
risk of cardiovascular events in apparently healthy people as
well as in patients with a previous cardiac event has been
the focus of very active research in the last decades. The
more the research progresses, the more it becomes clear
that the risk stratification process, due to its complexity,
can be effectively addressed only through a polyparametric
approach. This means that only a combination of a clinical,
instrumental, laboratory, and eventually invasive evaluations
exploring different biological conditions and pathways can be
really helpful in trying to identify and stratify the risk of each
individual subject. Although conventional risk prediction
algorithms aremade available based on the presence of major
cardiovascular risk factors identified in diseased populations,
authentic and accurate biomarkers of cardiovascular diseases
are still lacking. Among them chemokines are of particular
interest because as already described they seem to act as a
“working-network” involved in all stages of cardiovascular
response to injury, in deep linkage with the autonomic ner-
vous system (ANS). Since they work as a network it is difficult
to associate only one or few of them with cardiovascular risk.
Nevertheless, through the assessment of a predefined setting
of chemokines we could have the possibility to evaluate and
quantify pathological deviations of cardiovascular system
homeostasis even at very initial stages. The incremental
prognostic value of a polyparametric approach including an
evaluation of inflammatory markers has been clearly demon-
strated by Correia and colleagues in 2010 in the setting of
acute coronary syndromes [138]. Five cytokines [interleukin-
(IL-) 1𝛽, IL-6, IL-10, IL-12p70, and tumor necrosis factor-
(TNF-)𝛼 soluble receptor I], five chemokines (CXCL8, CCL5,
CXCL9, CCL2, and CXCL10), and CRP were measured at
admission in 87 patientswith non-ST segment elevation acute
coronary syndrome (NSTE-ACS). Individualswhodeveloped
events (death, nonfatal acute MI, and refractory unstable
angina) during hospitalization had significantly greater levels
of CRP, IL-1𝛽, IL-12, TNF-𝛼, CXCL8, CXCL9, and CCL2
compared with patients without events. These markers were
used to create an Inflammatory Score (by inputting one point
for each of these variables above the 75th percentile) to be
further adjusted for another score, called GRACE. GRACE
Score consists of 8 variables, 5 semiquantitative (age, systolic
blood pressure, heart rate, plasma creatinine, and Killip class)
and 3 dichotomic (positive necrosis markers, ST segment
deviation, and cardiac arrest at admission). After adjustment
for the GRACE Risk Score (considered as the most accurate
one in the setting of NSTE-ACS and largely used in clinical
practice), the Inflammatory Score independently predicted
events (OR = 1.80; 95% CI = 1.12–1.88). The incorporation
of the Inflammatory Score into the GRACE Score promoted
a 𝐶-statistics improvement from 0.77 (95% CI = 0.58–
0.96) to 0.85 (95% CI = 0.71–1.0), with a net reclassification
improvement of 13% (𝑝 = 0.007); on the other hand, when
only CRP was incorporated into GRACE, the increase on 𝐶-
statistics was not relevant (from 0.77 to 0.80). When we look
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at the plasmatic levels of each of the 11markers analyzed in the
score, we found very interesting results. CXCL8 was the most
varied chemokine between patients with and patients without
events; indeed CXCL8 levels were almost 4 times higher in
patients with events (median 37 pg/mL versus 10 pg/mL, 𝑝 =
0.003). This is not surprising considering the well-known
CXCL8 neutrophils attracting properties and their key role
in the development of reperfusion injury. Among the other
chemokines analyzed, both CCL2 and CXCL9 levels were
significantly higher in patients with events (𝑝 = 0.02). On
the other hand, CCL5 and CXCL10 levels were not different
in the two groups.While CXCL10 has never been evaluated in
the setting of acute coronary syndromes before, the negative
results for CCL5 (lack of association with events) were not
expected. However, considering the limited sample size, the
possibility of type II error as an explanation of these negative
findings could not be ruled out. Finally, the authors clearly
demonstrated that although the Inflammatory Score was
related with both peak troponin T and peak creatine kinase
MB, it remained a significant predictor of events even after the
adjustment for these parameters. The results of these studies,
although very preliminary, speak in favor of a multimarker
strategy (including chemokines) as opposed to a single-
marker approach. Unfortunately, the proposed Inflammatory
Score (in addition toGRACE Score), although very appealing
for the early management of NSTE-ACS, has never been
evaluated in other populations and themajority of the studies
performed in the last years focused on the evaluation of a
single chemokine, therefore missing the central point of the
network.
In 2012, De Jager and colleagues studied a larger popu-
lation of 609 ACS patients (56% infarcted patients with ST
elevation or STEMI, 33% non-STEMI, and 11% with unstable
angina) and demonstrated a significant prognostic value of
a pool of three chemokines (CCL3, CCL5, and CCL18) for
the short-term outcome [34]. The average follow-up time
was 189 days (189 ± 14.1 days) and patients were monitored
for the occurrence of fatal (𝑛 = 48) and nonfatal (𝑛 =
22) cardiovascular events (new acute coronary syndrome,
ACS, and/or coronary revascularization including both PCI
and CABG techniques). High levels of CCL3, CCL5, and
CCL18 were found to be independently associated with
short-term fatal events in patients with ACS. Furthermore,
the risk increased with a growing number of chemokines
in the highest concentration tertile, reaching hazard ratio
of 2.52 (95% CI: 1.11–5.65) in case of all of them in the
upper tertile. Interestingly, no relationships were observed
between chemokine levels and the risk of nonfatal events
during follow-up and a large difference between the timing
of fatal and nonfatal events during follow-up was noticed.
Namely, the majority of the fatal events occurred already
shortly after the start of follow-up.Themedian time-to-event
of fatal events was merely 5 days, whereas nonfatal events
occurred much later during follow-up with a median time-
to-event of 120 days. Considering the known predictors of
short-term fatal events (including clinical variables and CRP
levels), the combination of CCL3, CCL5, and CCL18, if added
simultaneously to the model, improved the 𝐶-statistics from
0.74 to 0.81 (𝑝 = 0.007). Obviously, the question of whether
this increased prognostic value is also of clinical relevance
deserves further investigation in studies with larger patient
populations.
Altogether, the results of these few studies, although
very preliminary, speak in favor of a multimarker strategy
as opposed to a single-marker approach. Furthermore, the
fact that scores including chemokine were found to be
consistently related to acute/subacute clinical outcome rather
than tomiddle term follow-up in the setting of acute coronary
syndromes seems to have a strong biological rationale and
point out the importance of the shift of the chemokine
homeostasis in driving the evolution of an acute myocardial
ischemia. Being so, by assessing a pool of chemokine we
could have the possibility to predict an adverse biological
response (e.g., reperfusion injury) immediately before it is
taking place andwe could identify high risk patients whomay
require amore aggressive treatment and/or new experimental
interventions (e.g., VNS).
7. Conclusion
In the past two decades the evidence suggesting a role for
inflammation in the pathogenesis of cardiovascular diseases
has been progressively increasing. Most data were related
initially to the development of atherosclerosis and to the
acute instability of atherosclerotic plaques. As reviewed in
this paper, numerous studies now demonstrate a profound
involvement of inflammatory processes in a variety of
cardiovascular manifestation of diseases such as myocar-
dial ischemia, heart failure, atrial fibrillation, and malig-
nant ventricular arrhythmias. Parallel with the increased
understanding of the role of inflammation, data have been
gathered on the implication of chemokines in these pro-
cesses. Chemokines act as a complex network connecting
the cardiovascular system with the immune system and
the autonomic nervous system. Although the original goal
of this extensive crosstalk is to maintain homeostasis and
to coordinate the best response to injury, it appears that
unbalanced or exaggerated responses may actually lead to a
progression of the disease and contribute to an acute and
potentially life-threatening manifestation. Many aspects of
the involvement of chemokinesmust still be elucidated before
their role can be considered clarified. Moreover, further data
are required before their evaluation can be used clinically
in the prediction of the disease, in risk stratification of
patients, and possibly in paving the way to new therapeutic
strategies. In many circumstances the “chicken and egg”
question has not been solved, being still uncertain whether
specific chemokines are involved in favoring the disease or
rather are the result of the disease, being triggered by it.
Also, it has become increasingly evident that chemokines
represent a very complex network and that it would be naı̈ve
to believe that by simply assessing a single one of them a
significant improvement in the comprehension of a disease
process or in the risk stratification of individual subjects
may be derived. This goal may be possibly achieved using
a multidimensional evaluation in which multiple markers
including panels of appropriately selected chemokines are
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assessed together. Should we achieve this goal we would have
probably reached the heart of the problem for a better













IDC: Idiopathic dilated cardiomyopathy
IR: Ischemia and reperfusion
LQTS: Long QT syndrome
LV: Left ventricle
NYHA: New York Heart Association
NE: Norepinephrine
NGF: Nerve growth factor
NPY: Neuropeptide Y
NSTE-ACS: Non-ST segment elevation acute coronary
syndrome
PCI: Percutaneous coronary intervention
ROS: Radical oxygen species
SP: Substance P
VNS: Vagal nerve stimulation
𝛼-7nAChR: Alpha-7-n acetylcholine receptor
VF: Ventricular fibrillation.
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